Opus Genetics (IRD) EPS (Diluted) Growth (3y) (2019 - 2026)
Powered by 
Analysis
Opus Genetics (IRD) EPS (Diluted) Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 82.91% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 36.83% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -36.81% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.51% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | 32.53% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.53% |
| Mar 31, 2026 | -39.71% |
| Dec 31, 2025 | -27.23% |
| Sep 30, 2025 | -3.78% |
| Jun 30, 2025 | 22.61% |
| Mar 31, 2025 | 11.52% |
| Dec 31, 2024 | -45.72% |
| Sep 30, 2024 | -4.82% |
| Jun 30, 2024 | 16.92% |
| Mar 31, 2024 | 56.71% |
| Dec 31, 2023 | 61.87% |
| Sep 30, 2023 | 40.01% |
| Jun 30, 2023 | 17.95% |
| Mar 31, 2023 | 31.76% |
| Dec 31, 2022 | 22.18% |
| Sep 30, 2022 | 57.90% |
| Jun 30, 2022 | 59.22% |
| Mar 31, 2022 | 53.81% |
| Dec 31, 2021 | 55.15% |
| Sep 30, 2021 | 68.60% |